Seeking Alpha

Ferumoxytol well tolerated in Merrimack Phase I trial

  • AMAG Pharmaceuticals' Ferumoxytol, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to treatment with the company's MM-398 cancer therapy in a Phase I trial conducted by Merrimack Pharmaceuticals (MACK).
  • Almost all the tumor lesions that shrank after MM-398 treatment were associated with higher levels of ferumoxytol, MACK says.
  • Shares are +1.4%. (PR)
This was corrected on 04/08/2014 at 03:05 PM.
Comments (2)
  • pat walsh
    , contributor
    Comments (209) | Send Message
     
    :) I love my Mack.
    8 Apr, 04:43 PM Reply Like
  • Ranjan Pokharel
    , contributor
    Comment (1) | Send Message
     
    This stock will double soon
    9 Apr, 02:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|